Your browser doesn't support javascript.
loading
A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies.
Jian, Cheng-Zhe; Lin, Li; Hsu, Chia-Lang; Chen, Yu-Hsin; Hsu, Chiun; Tan, Ching-Ting; Ou, Da-Liang.
Afiliación
  • Jian CZ; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan.
  • Lin L; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan.
  • Hsu CL; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan; Department of Medical Research, National Taiwan University Hospital, Taipei 10051, Taiwan.
  • Chen YH; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan; Stem Cell Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei 10051, Taiwan.
  • Hsu C; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei 10051, Taiwan.
  • Tan CT; Stem Cell Core Laboratory, Center of Genomic Medicine, National Taiwan University, Taipei 10051, Taiwan; Department of Otolaryngology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan; Department of Otolaryngology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu 302
  • Ou DL; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan; YongLin Institute of Health, National Taiwan University, Taipei 10051, Taiwan. Electronic address: dlou@ntu.edu.tw.
Drug Discov Today ; 29(3): 103893, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38272173
ABSTRACT
CD40, a novel immunomodulatory cancer therapy target, is expressed by B cells, macrophages, and dendritic cells (DCs) and mediates cytotoxic T cell priming through the CD40 ligand. Some tumors show promising responses to monotherapy or combination therapy with agonistic anti-CD40 antibodies. The development of improved anti-CD40 antibodies makes CD40 activation an innovative strategy in cancer immunotherapy. In this review, we trace the history of CD40 research and summarize preclinical and clinical findings. We emphasize the ongoing development of improved anti-CD40 antibodies and explore strategies for effective combination therapies. Guided by predictive biomarkers, future research should identify patient populations benefiting the most from CD40 activation.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antígenos CD40 / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Drug Discov Today Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Taiwán
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Antígenos CD40 / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Drug Discov Today Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Taiwán